Voyager Therapeutics (VYGR) Cash from Operations (2014 - 2026)

Voyager Therapeutics has disclosed Cash from Operations across 13 years of filings, most recently posting 33419000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 33419000.0, up 11.81% year-over-year; the trailing twelve-month figure through Mar 2026 was 127991000.0 (down 14.31% YoY), and the FY2025 annual result was 132467000.0, down 765.23% from the prior year.
• Cash from Operations came in at 33419000.0 for Q1 2026 at Voyager Therapeutics, down from 30263000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 123565000.0 in Q1 2023 to a low of 37895000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 21051000.0 (2023), against an average of 6810941.18.
• Across the five-year window, Cash from Operations jumped 261.67% in 2022 and tumbled 3682.04% in 2024, its largest moves.
• Voyager Therapeutics' Cash from Operations stood at 12244000.0 in 2022, then sank by 94.05% to 23760000.0 in 2023, then jumped by 38.85% to 14529000.0 in 2024, then slumped by 108.29% to 30263000.0 in 2025, then declined by 10.43% to 33419000.0 in 2026.
• The last three Cash from Operations figures came in at 33419000.0 (Q1 2026), 30263000.0 (Q4 2025), and 31048000.0 (Q3 2025), per Business Quant data.